TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03169790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study: NCT03248882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304, Experimental Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304, Experimental Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304, Experimental Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304, Experimental Drug
Study: NCT01656200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis vaccine SA14-14-2
Description: Live attenuated Japanese encephalitis vaccine SA14-14-2
Study: NCT01457482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy and therapeutic conversations
Description: Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
Study: NCT00721409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study: NCT02977793

Intervention type: DEVICE
Intervention: Konan CellChek XL Specular Microscope

Intervention type: DEVICE
Intervention: Konan CellChek XL Specular Microscope
Study: NCT02400801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: gonadotropin-releasing hormone (GnRH) agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol + dienogest
Description: oral oestroprogestogen
Study: NCT01098084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/day, one hour intravenous infusion, every day during 5 days
Study: NCT02033759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Impedance Testing
Description: Participants in the BIA Arm will also undergo bio-impedance testing with this device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaire
Description: 21 item questionnaire

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Questionnaire
Description: 21 item questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Circumferential Measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Circumferential Measurements
Study: NCT01162733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 15mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 30mg/kg
Study: NCT01457482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic conversations
Description: Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
Study: NCT03412201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Care
Description: Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
Study: NCT05045651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
Description: gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
Description: gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
Study: NCT04638920

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03864198

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Genante
Description: A dietary supplement for male infertility
Study: NCT00656708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kerlix AMD gauze
Description: Use Kerlix AMD gauze as the wound dressing for the entire burn unit
Study: NCT02252770

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide supplement
Description: Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will not contain nitric oxide supplement.
Study: NCT03582527

Intervention type: OTHER
Intervention: all study participants
Description: patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
Study: NCT00873028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Hospital Cardiopulmonary Rehabilitation
Description: The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
Study: NCT03858829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric analysis
Description: Psychometric analysis
Study: NCT03374449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuation of the RAS-inhibitors
Description: drug intake

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: discontinuation of the RAS-inhibitors
Description: no drug intake
Study: NCT03435913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard PEEP ventilation
Description: During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard PEEP ventilation
Description: During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched PEEP ventilation
Description: During mechanical ventilation PEEP is matched to IAP level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched PEEP ventilation
Description: During mechanical ventilation PEEP is matched to IAP level
Study: NCT02950610

Intervention type: DEVICE
Intervention: Breath analysis - electronic signature Breath-print
Description: Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.

Intervention type: DEVICE
Intervention: Breath analysis - electronic signature Breath-print
Description: Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.

Intervention type: DEVICE
Intervention: Breath analysis - electronic signature Breath-print
Description: Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
Study: NCT04326322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine Intake
Description: Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
Study: NCT03400111

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol-extra
Description: Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
Study: NCT04680195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months.
Study: NCT03660644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp, Pedometer and Step Diary
Description: Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks.
Study: NCT04202367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg.kg-1 bupivacaine 0.25%
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg.kg-1 bupivacaine 0.125%
Description: Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
Study: NCT00617552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: 60 ml IV infusion over 30 minutes
Study: NCT03241459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surmodics SurVeil DCB
Description: Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic IN.PACT Admiral DCB
Description: Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
Study: NCT01562041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg
Description: Ranolazine 500 mg, oral tablet, b.i.d.
Study: NCT02451176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Davol Bard Soft Mesh synthetic
Description: soft mesh synthetic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeCell Strattice Reconstructive Tissue Biologic
Description: biologic mesh
Study: NCT00130325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 900mg, tablets, twice a week for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH 900mg twice weekly for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Isoniazid tablets 300mg
Description: Isoniazid BP 0mg twice weekly for 6 months
Study: NCT04246021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Description: intravenous iron formulation
Study: NCT02949362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05mg/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
Study: NCT01146600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin followed by placebo
Description: Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo then Clarithromycin
Description: Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
Study: NCT00528619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Description: Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
Study: NCT04315558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin Inhalation Solution [Yupelri]
Description: nebulized drug comparison

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide
Description: nebulized drug comparison
Study: NCT00617552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 20 micrograms/kg IV 2ml/minute for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 40 micrograms/kg IV 2 ml/minute for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 80 micrograms/kg IV 2ml/minute for 30 minutes
Study: NCT03670095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactose-free memantine
Description: Lactose-free memantine tablet, 10 mg; orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Lactose-containing memantine tablet, 10 mg, orally as a single dose
Study: NCT00662142

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
Study: NCT04851639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wolverhampton Assessment Tool
Description: a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
Study: NCT03596762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: BAY3427080 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: BAY3427080 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: BAY3427080 capsules
Study: NCT00617552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 160 micrograms/kg IV 2ml/minute over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 320 micrograms/kg IV 2ml/minute for 30 minutes
Study: NCT03596762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: BAY3427080 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT01378689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Storytelling online video
Description: patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
Study: NCT03225326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Computer controlled 4% articaine delivery by Anaeject
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 4% articaine delivery by carpule syringe
Description: Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
Study: NCT00564577

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CFA/I and CS17 challenge strain
Description: Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
Study: NCT00540865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Description: The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management (CM)
Description: Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management (CM)
Description: Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
Study: NCT03071237

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
Study: NCT04148651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CO2RE® System
Description: The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
Study: NCT01208103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given CVC
Study: NCT04601025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yoghurt
Description: 200 ml plain full-fat yoghurt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea+Yoghurt
Description: 80 ml plain full-fat yoghurt + 70 gr cooked chickpea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat+Yoghurt
Description: 80 ml plain full-fat yoghurt + 100 gr cooked oat
Study: NCT03490838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-R2
Description: radio-ligand therapy
Study: NCT00617552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 480 micrograms/kg IV 2ml/minute over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 600 micrograms/kg IV 2ml/minute for 30 minutes
Study: NCT02897557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulet Artificial Pancreas (AP) System